Intuitive Surgical (ISRG – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Patrick Wood from Morgan Stanley maintained a Buy rating on the stock and has a $650.00 price target.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Patrick Wood has given his Buy rating due to a combination of factors including stable general surgery volumes and the promising potential of Intuitive Surgical’s robotic systems. Despite a noted decrease in bariatric surgery volumes attributed to the rise in GLP-1 demand, the normalization of growth is anticipated in the future.
The Dv5 system, while not drastically different from the Xi system, offers beneficial features like force feedback technology, which can be particularly advantageous in training new surgeons. This innovative technology, along with the promising outlook for endoluminal surgery as the next big frontier, supports the Buy rating for Intuitive Surgical.
In another report released on February 12, Raymond James also reiterated a Buy rating on the stock with a $688.00 price target.